---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-025559"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T12:14:13.058660+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics FY2024 net loss $126.6M; discontinues ELiPSE-1, focuses on CNTY-308

## Summary
- Net loss $126.6M for FY2024 ($136.7M in 2023); cash $220.1M, runway into Q4 2026.
- Discontinued ELiPSE-1 Phase 1 trial for CNTY-101 in R/R NHL; data not transformational.
- Pipeline re-prioritized to four programs led by CNTY-308 (CD19 CAR-iT); IND-enabling studies mid-2025.
- First patient dosed in CALiPSO-1 Phase 1 trial for CNTY-101 in autoimmunity; CARAMEL IIT to start mid-2025.
- Collaboration revenue from BMS $6.6M; R&D expenses $107.2M (up from $92.7M) driven by trial and manufacturing costs.

## SEC filing metadata
- accession: 0001104659-25-025559
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465925025559/0001104659-25-025559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465925025559/tm259654d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-025559
- JSON: https://secwatch.observer/filing/0001104659-25-025559.json
- Plain text: https://secwatch.observer/filing/0001104659-25-025559.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.